– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer expected to initiate by the end of 2022 – – MARIO-P, a study designed to expand ...
There’s perhaps never been a better time to be an office broker in South Florida. While industry leaders fretted over the future of the office in the wake of the pandemic, South Florida brokers didn’t ...
WINDSOR, Conn.--(BUSINESS WIRE)--Infinity Fuel Cell and Hydrogen, Inc. today revealed that it is actively exploring new markets for its air-independent non-flow-through hydrogen fuel cells in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback